We are live on ! Find out more
TARA icon

Protara Therapeutics

41 hedge funds and large institutions have $69.3M invested in Protara Therapeutics in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 19 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,788% more call options, than puts

Call options by funds: $151K | Put options by funds: $8K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

12.61% less ownership

Funds ownership: 75.94%63.33% (-13%)

16% less funds holding

Funds holding: 4941 (-8)

47% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 17

48% less capital invested

Capital invested by funds: $134M → $69.3M (-$64.7M)

58% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 19

Holders
41
Holders Change
-8
Holders Change %
-16.33%
% of All Funds
0.71%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
9
Increased
8
Reduced
19
Closed
17
Calls
$151K
Puts
$8K
Net Calls
+$143K
Net Calls Change
+$143K

TARA Hedge Fund Activity: Q2 2021 in Review

41 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q2 2021, worth a combined $69.3M — down 48% from $134M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of TARA and 9 opened new positions — a net loss of 8 holders — while 19 trimmed existing stakes and 8 added.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $1.5M. The largest seller was Artisan Partners, exiting entirely with an estimated $5.98M sold.

  • 41 institutional investors held Protara Therapeutics (TARA) as of Q2 2021, down from 49 in Q1 2021.
  • Funds reported $69.3M of Protara Therapeutics stock for Q2 2021, down 48% quarter-over-quarter.
  • 9 funds opened new Protara Therapeutics positions in Q2 2021 and 17 closed out, a net change of -8 holders.
  • The largest Protara Therapeutics buyer in Q2 2021 was Goldman Sachs, an estimated $1.5M added.
  • The largest Protara Therapeutics seller in Q2 2021 was Artisan Partners, an estimated $5.98M sold.

Based on aggregated 13F filings for Q2 2021.